Recruiting Cancer Clinical Trials - Head and Neck

BCA101X301

A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Description: This study is testing whether adding the new medicine ficerafusp alfa (BCA101) to pembrolizumab works better than pembrolizumab alone or people with PD‑L1‑positive head and neck cancer that has come back or spread.”
Study Phase: Phase 2
Principal Investigator: Dr Cliona Grant
Further information